B-CELL LYMPHOMA
Clinical trials for B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New strategy aims to keep lymphoma at bay after powerful CAR-T treatment
Disease control Not yet recruitingThis study is looking at whether taking the drug zanubrutinib after receiving CAR-T cell therapy helps keep B-cell lymphoma from coming back. It will involve about 40 adults who have already had or are scheduled to get CAR-T treatment. The main goal is to see if this maintenance …
Matched conditions: B-CELL LYMPHOMA
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Swiss hospital tests 'Double-Target' immune therapy for tough blood cancers
Disease control Not yet recruitingThis early-stage trial is testing the safety of a new, locally-made CAR-T cell therapy designed to attack two targets (CD19 and CD20) on cancer cells. It is for adults with advanced B-cell leukemias or lymphomas who have relapsed after or cannot access standard treatments, includ…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New 'Living Drug' trial offers hope for tough blood cancers
Disease control Not yet recruitingThis early-stage study is testing a new type of personalized cell therapy for adults whose leukemia or lymphoma has returned or hasn't responded to standard treatments. Doctors will modify a patient's own immune cells to better target and fight their cancer, then infuse them back…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Experimental drug targets tough blood cancers in early safety trial
Disease control Not yet recruitingThis early-stage trial is testing a new drug called LY4152199 in people with B-cell lymphomas that have returned or didn't respond to previous treatments. The main goals are to find a safe dose and see if the drug shows any signs of helping control the cancer. The study will enro…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC